INTRODUCTION
Failure of endocrine therapy for metastatic prostatic carcinoma may be accompanied with alterations in transmission of androgen signals. The presence of a mutant AR3 in LNCaP cells (1) and the absence of the AR transcript in PC-3 and DU-145 cells (2) reflect impairments in the androgen-signaling chain in advanced prostatic carcinoma. More over, the existence of AR point mutations in primary prostatic tumors (3â€"5) and tumor metastases (5) and the presence ofAR with decreased numbers of CAG repeats in the NH2 terminus in a specimen derived from a patient showing paradoxical response to the antiandrogen flutamide (6) support the hypothesis that structural changes of the AR may play a role in prostatic tumor genesis and progression. The two mutant prostatic ARs, Met7t5 and Ala877, are activated in addition to androgens by a wide spectrum of steroid hormones and nonsteroidal antihormones (1, 4) . Because of these findings, the question arises whether another type of aberrant stimulation of the AR exists, namely, receptor activation which is independent of androgens. The ER and the PR, which belong to the same superfamily of ligand-induced transcription factors as the AR, mediate gene transcription not only in response to estradiol and progesterone, respectively, but also in re sponse to IGF-I, EGF, cAMP, protein kinase activators, and dopamine (7â€"li). Cross-talk between a growth factor and the AR may have several implications on the pathophysiology of malignant and initially hormone-dependent prostatic carcinoma; above all, in a hormone depleted environment androgen-independent AR activation may acti vate the androgen-signaling pathway. The aim of this study was to investigate a possible interaction of growth factors with the androgen signal transduction cascade in prostatic tumor cell lines.
MATERIALS AND METHODS
Cell Lines. DU-145 and LNCaPprostaticcarcinomacell lines were rou tinely cultured in RPMI supplemented with 5% fetal calf serum and antibiotics at 37Â°C in an atmosphere of 5% CO2 in air.
Growth Factors and Hormones. IGF-I, IGF-II, and KGF were purchased from Boehringer Mannheim (Germany), bFGF was purchased from Upstate Biotechnology (Lake Placid, NY), and EGF was purchased from GIBCO BRL (Paisley, United Kingdom). Methyltrienolone was obtained from New England Nuclear (Dreieichenhain, Germany) and casodex was obtained from ICI (Cheshire, United Kingdom).
Cotransfections and CAT Assays. DU-145 cells were grown on 12-well plates. CAT reporter genes were driven either by artificial promoters consisting of one or two AREs in front of a TATA box or by the naturally occurring PSA promoter (12) , which contains an ARE at â€" 170 to â€" 156. Reporter plasmids were mixed with AR expression vectors at a ratio of 10:1. Liposome-mediated transfection was performed under serum-free conditions. The DNA solution was mixed with Lipofectamine transfection reagent (GIBCO BRL, Paisley, United Kingdom; 3 @Ll/@.Lg plasmid DNA) and added to the cells. After an incubation period of about 12 h, the medium was supplemented with 5% charcoal-treated serum. Methyltrienolone or growth factors were added 8 h later. About 32 h after supplementation, the medium was removed and the cells were frozen. CAT activity was assessed as described previously (4 period of 72 h, the medium was removed and the PSA level was assessed by an enzyme immunoassay (Abott, Wiesbaden, Germany). PSA levels were corrected with respect to equal cell numbers which were determined by a nonradioactive cell viability assay (Biomedica, Vienna, Austria). In order to evaluate possible effects of treatment on the level of AR expression, we also performed AR-binding assays with radioactively labeled methyltrienolone.
The assay procedure was described elsewhere (4) .
RESULTS
The effects of the synthetic androgen methyltrienolone and of IGF-I, IGF-II, bFGF, KGF, and EGF on AR-mediated transactivation of the androgen-inducible promoter containing two AREs in front of a TATA box were evaluated in DU-145 cells (Fig. 1) . These cells were derived from a brain metastasis of a prostate cancer patient and represent a late tumor stage. They do not express endogenous steroid receptors (13) . In these cells the reporter CAT gene and the AR expression vector were transiently coexpressed. Maximal stimulation of the AR in cotransfection-transactivation assays by androgen was achieved with 5 nM synthetic androgen methyltrienolone. IGF-I, at a concentration of 50 ng/ml, stimulated AR-mediated CAT activity to the same extent as methyltrienolone. At a concentration of 25 ng/ml, IGF-I displayed only a negligible effect on AR-mediated gene tran scription in this experimental system. When 50 ng/ml of KOF were added, CAT activity increased to a level of about two-thirds of that achieved by methyltrienolone or IGF-I. EGF also showed minor stimulatory effects in cotransfection-transactivation assays, whereas IGF-II and bFGF did not cause any increase in CAT activity. In all experiments in which the empty expression vector was cotransfected stimulatory effects of the three polypeptide growth factors on reporter gene transcription are mediated through the AR.
We further investigated whether growth factors had similar effects on AR activation of the PSA promoter, a naturally occurring andro gen-regulated promoter, which contains one ARE. IGF-I (50 ng/ml) stimulated AR-mediated PSA gene promoter transcription (Fig. 2) . This effect was slightly less pronounced than in the experiments in which the promoter containing two AREs was used. KGF, EGF, IGF-II, and bFGF were ineffective with the PSA promoter. The fact that the nonsteroidal antiandrogen casodex was able to suppress IGF-I-induced CAT activity in experiments with the PSA gene pro moter confirms that this effect of IGF-I is mediated by the AR (Fig. 2) .
The promoter-dependent differences in activation of reporter gene transcription in response to KGF and EGF prompted us to perform cotransfection experiments in which the CAT reporter gene was driven by an artificial promoter containing one ARE in front of a TATA box. Only IGF-I stimulated CAT activity in this experiment (Fig. 3) . Taken together, our data show that IGF-I is able to activate AR-mediated reporter gene transcription irrespectively of the nature of the promoter driving the CAT gene. KGF and EGF, however, were effective only with the promoter containing two AREs in front of a TATA box. In all three experimental systems, 5 ni@i methyltrienolone and 50 ng/ml of IGF-I were also applied simultaneously to determine whether both AR activators displayed additive effects. There was, however, no increase in reporter gene activity above the maximal level which was achieved with 5 nM methyltrienolone (Figs. 1â€"3) .
In order to confirm results with transiently expressed AR with those obtained with an endogenously expressed AR, we evaluated effects of growth factors on AR-mediated expression in prostatic tumor cells which contain endogenous AR. Among established human prostatic tumor cell lines, only LNCaP contains high amounts of AR. Since our efforts to measure CAT activity in LNCaP cells after introduction of the CAT reporter gene were not successful, we tested AR activation indirectly by measurement of the PSA level after treatment with androgen or one of the growth factors. PSA secretion in the LNCaP cell line has been previously shown to be AR mediated (14) . The molecular mechanism involved in the interaction between growth factors and steroid receptors remains to be elucidated. An increase in overall receptor phosphorylation might be a possible explanation. Analysis of deletion mutants of the PR provided evidence that dopamine effects on PR activation are accompanied with phos phorylation of a specific amino acid in the COOH terminus (11) . Estradiol and IGF-I were found to stimulate ER phosphorylation, but the same effect was observed after exposure of the ER to the antics trogen IC! 164,384 (7). Thus, the relationship between phosphoryla tion and steroid receptor activation is as yet unclear.
Previous recognition that IGF-I directly activates the ER might provide an explanation for some tumor-promoting effects of this growth factor in breast cancer. IGF-I may stimulate growth of breast cancer cells in the absence of estrogen (16) . This growth factor can synergize with estradiol in enhancing PR synthesis in the breast cancer cell line MCF-7 (17). The results presented in this paper suggest a similar interplay between androgen and growth factor shown). At a concentration of 5 nM methyltrienolone, PSA secretion was maximally induced. Among growth factors tested, only IGF-I was able to enhance PSA secretion (Fig. 4) . The synthetic androgen methyltrienolone, at a concentration of 5 nM, stimulated PSA secretion approximately 8-fold, while IGF-I, at a concentration of 50 ng/ml, increased the PSA level in the supernatant 5-fold. As expected, casodex (5 p.M) abolished these stimulatory effects of androgen and IGF-I (Fig. 4) . At a concentration of 1 p.M.casodex reduced the PSA level to approximately 20% of the maximal value (data not shown). Simultaneous addition of 5 nM methyltrienolone and 50 ng/ml of !GF-I did not increase the PSA level over that achieved by stimulation with 5 nM methyltrienolone alone (Fig. 4) . bFGF and EGF exerted slight inhibitory effects on PSA secretion (Fig. 4) . The increase in the PSA level achieved by IGF-I cannot be explained by an increase in cell number, since the cell viability assays did not reveal stimulatory effects of this growth factor on LNCaP cell growth during the exper iment. We also observed no significant differences in the AR content, as assessed by binding assays (data not shown). Thus, stimulatory effects of IGF-I on PSA secretion cannot be attributed to an increase of the level of AR protein. Taken 
DISCUSSION
The major finding of this study is that three polypeptide growth factors, namely, IGF-I, KGF, and EGF, can activate the AR directly in the absence of androgen. IGF-I turned out to be more potent than KGF, which, in turn, was more effective than EGF in this respect. IGF-I was effective with all androgen-inducible promoters tested in our experiments, whereas KGF and EGF did not elicit AR-dependent transcriptional activation of promoters containing one ARE. The findings that the pure antiandrogen casodex is capable of reducing the CAT activity induced by IGF-I, KGF, and EGF to the basal level and that no increase in CAT activity was observed in cells in which the empty expression vector was cointroduced with the reporter gene signaling pathways in the prostate. This cross-talk is of particular importance in prostatic carcinoma. It has been shown that lack of AR in advanced tumors is not the reason for failure of endocrine therapy of prostate cancer (18) . The majority of tumors, androgen-dependent as well as androgen-independent ones, contain immunoreactive AR protein. Moreover, recent observations with LNCaP cells which were cultured for a long time in androgen-depleted medium even suggest an up-regulation of AR expression by androgen deprivation (19) . Under these conditions, aberrant AR activation by growth factors might be facilitated and thus contribute to the failure of androgen ablation therapy. Another possible mechanism was described recently when mutated ARs with a broad hormonal activation spectrum were de tected in prostatic carcinoma specimens (3â€"6).
Effects of IGF-I, which displayed strong stimulation on the AR mediated reporter gene transcription, on growth of prostatic cells were investigated previously (20â€"22).IGF-I was found to stimulate prolif eration of prostatic epithelial cells in primary cultures more efficiently than IGF-II and far more strongly than insulin (20) . In view of our results, it is possible that at least a part of these growth stimulatory effects is due to activation of the AR. Recently, Bami et a!. (23) provided evidence that IGF-I mRNA is localized in stroma, whereas the IGF-I receptor is detected in the epithelial compartment. These findings imply a paracrine mode of action of IGF-I in the prostate. In contrast to findings in primary cultures, addition of exogenous IGF-I does not stimulate growth of androgen-responsive LNCaP cells (21, 22) . In our experiments we also did not see any growth stimulatory effects in LNCaP cells. With androgen-independent prostatic tumor cell lines PC-3 and DU-145, contradictory effects of exogenous IGF-I on growth were reported (21, 22) . Whereas Iwamura et a!. (21) observed stimulation of DNA synthesis by IGF-I, Pietrzkowski et a!. (24) . Recent findings suggest that PSA is an IGF-binding protein-3 protease (25). In patients with metastatic pros tatic cancer, decreased levels of IGF-binding protein-3 in serum were measured (26) . Thus, PSA may enhance release of IGF-I and, mdi rectly, potentiate its stimulatory effects on the AR. KGF, which was effective in stimulation of the reporter gene activity in experiments in which the CAT gene was driven by the promoter consisting of two AREs in front of a TATA box, belongs to the family of heparin-binding growth factors. The source of KGF in the prostate gland is the stromal cells, whereas the epithelial cells express specific receptors for this growth factor (27) . Expression of KGF receptors correlates inversely with an evolution toward in creased malignancy of the Dunning R.3327PAP prostatic tumor (27) . KGF appears to be an essential element in the transmission of andro gen stimuli. The primary target of androgen action in the prostate is the cells in the mesenchymal compartment (28) . In cultures, prostatic epithelial cells respond to dihydrotestosterone only in the presence of KGF; therefore, KGF is considered to have properties of a stromal to epithelial cell andromedin (27) . Because of our findings the question of whether activation of the AR by KGF is an integral part of this signaling pathway has to be addressed. Unlike KGF, bFGF, which also belongs to the heparin-binding growth factor family, did not exert any stimulatory effect on AR-mediated gene transcription. This can not be due to a lack of bFGF receptor expression. LNCaP as well as DU-145 cells were shown to express bFGF receptors and to respond to exogenous bFGF (29) .
EGF effects on transcription of the androgen-responsive reporter gene were less pronounced when compared with those of IGF-I and KGF. These results are in concordance with experiments in which EGF stimulation of ER-mediated transcription was studied (8) .
Unfortunately, we were not successful in measuring reporter gene activity after addition of growth factors in LNCaP cells which contain endogenous AR. Similar observations regarding transfection of LN CaP cells with a reporter expression vector were previously reported by Riegman et aL (12) . Therefore, we evaluated AR activation in the LNCaP cell line indirectly, upon measurement of PSA protein secre tion. Regulation of PSA glycoprotein is mediated via the AR (14) . Previous studies revealed that hormones which activate the AR in LNCaP cells also increase the PSA mRNA level and protein secretion (1, 14, 30) . Our results demonstrated an up-regulation of the PSA protein by IGF-I, whereas other growth factors tested did not stimulate PSA secretion. bFGF and EGF were previously found to decrease the PSA level in LNCaP cells slightly below the values measured in a conditioned medium of untreated cells (14) . This coincides with our results.
Previous studies of cross-talk between the androgen-signaling cas cade and growth factors in the prostate have reported androgen mediated regulation of growth factors EGF (31), acidic fibroblast growth factor (32), KGF (27) , and transforming growth factor-13 (33) expression. Our findings provide the first evidence of the existence of a signaling pathway between growth factors and the AR. The results presented in this study may serve as a basis for further experiments dealing with implications of AR activation by IGF-I, KGF, and EGF in an environment of androgen deficiency. This may influence the design of new modalities of endocrine therapy for advanced prostatic carcinoma.
